Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on oncology that reached the public markets through a merger with Panacea Acquisition Corp. II, a healthcare-focused special purpose acquisition company that completed its IPO in 2020 and was sponsored by Panacea Acquisition Management II LLC. The 10-Q filed on November 16, 2020, under accession number 0001213900-20-037163, reflects the company's financial disclosures during the SPAC transaction period. Founded by David Hung, who previously led Medivation, Nuvation Bio targets novel cancer therapies and sits squarely in the biopharma and life sciences sector. For comprehensive filing history, deal terms, and sponsor analytics on NUVB and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.